期刊文献+

苯磺酸贝他斯汀的不对称合成 被引量:8

Asymmetry Synthesis of Bepotastine Besilate
下载PDF
导出
摘要 用(S)-[Ru(BINAP)Cl2]2(NEt3)作催化剂,不对称氢化还原(4-氯苯基)-(吡啶-2-基)-甲酮得到(S)-(+)-(4-氯苯基)-(吡啶-2-基)-甲醇,与4-(4-溴哌啶-1-基)丁酸乙酯缩合,再经水解、成盐得到抗过敏药苯磺酸贝他斯汀,总收率57%。 Bepotastine besilate was synthesized from (4-chlorophenyl)-(pyridine-2-yl)-methanone by asymmetric hydrogenation with (S)- [Ru (BINAP) Cl2] 2 (NEt3) as the catalyst to give (S) - (+)- (4-chlorophenyl)- (pyridine-2-yl)-methanol, which was subjected to condensation with ethyl 4-(4-bromopiperidin-1-yl) butyrate followed by hydrolysis and salification with an overall yield of 57 %.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2006年第11期726-727,755,共3页 Chinese Journal of Pharmaceuticals
关键词 苯磺酸贝他斯汀 抗过敏药 不对称合成 bepotastine besilate antiallergic agent asymmetry synthesis
  • 相关文献

参考文献5

  • 1Narita H,Kikuchi M,Asahi T,et al.General pharmacology of bepotastine besilate[J].Jpn Pharmacol Ther,1997,25 (4):907-924.
  • 2Koda A,Kita JI.Piperidine and piperazine derivatives,process for preparing the same and pharmaceutical compositions containing the same[P].EP:335586,1989-10-10.(CA 1990,112:1188501)
  • 3Kita JI,Fujiwara H.Acid-addition salts of optically active piperidine compound and process for producing the same[P].EP:0949260,1999-10-13.(CA 1998,129:122577)
  • 4Chen C,Reamer R,Chilenski J,et al.Highly enantioselective hydrogenation of aromatic-heteroaromatic ketones[J].Organic Lett,2003,5 (26):5039-5042.
  • 5Corey E,Helal C.Asymmetric synthesis of (S)-carbinoxamine.New aspects of oxazaborolidine-catalyzed enantioselective carbonyl reduction[J].Tetrahedron Lett,1996,37 (32):5675-5678.

同被引文献35

  • 1杨吉春,刁杰,葛童,刘长令.吡啶类农药最新研究进展[J].农药,2007,46(1):1-9. 被引量:33
  • 2KITA J I, FUJIWARA H, TAKAMURA S, et al. Acid-addition salts of optically active piperidine compound and process for producing the same:EP,0949260[ P]. 1999 - 10 - 13.
  • 3CDER Dermatologic and Ophthalmic Drugs. Bepreve^TM 1.5% (bepo otastine besilate ophthalmic solution ) [ EB/OL ]. [2009-06]. http://www. fda. gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM 176356. pdf.
  • 4ISTA Pharmaceuticals Inc. Bepreve( bepotastine besilate) prescribing information [ EB/OL]. [ 2009 - 08 ]. http://www. istavision. com/pdf/Bepreve_insert. pdf.
  • 5陈其国,高宏飞,杨刚,徐南平.吡啶二亚胺钌配合物催化酮的氢转移氢化反应[J].南京工业大学学报(自然科学版),2007,29(4):7-10. 被引量:3
  • 6郭翠莲,吴悦,周益明,李一志,郑和根.联吡啶钌(Ⅱ)配合物的合成、晶体结构及其在染料敏化太阳能电池中的应用[J].无机化学学报,2007,23(10):1771-1776. 被引量:9
  • 7Bergmann MT, Williams JI, Gomes PJ. Treatment of allergicconjunctivitis with bepotastine besilate ophthalmic solution1.5% [J]. Clin Ophthalmol, 2014, 8: 1495-1505.
  • 8Kita JI, Fujiwara H,Takamyura S,et al. Acid-addition saltsof optically active piperidine compound and process forproducing the same: EP, 0949260 [P]. 2000-03-15.
  • 9Eda S, Kita J, Takamura S, et al. Piperidine derivative,production thereof and pharmaceutical composition containingthe same derivative: JP, H0225465 [P]. 1990-01-26.
  • 10Park SR. A new improved preparation method for thepreparation of optically active piperidine compound: KR,20120116082 [P], 2012-10-22.

引证文献8

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部